B. Riley resumed coverage on Arbutus Biopharma with a new price target
$ABUS
Biotechnology: Pharmaceutical Preparations
Health Care
B. Riley resumed coverage of Arbutus Biopharma with a rating of Buy and set a new price target of $7.00 from $8.00 previously